A Phase 3 interventional study of Secukinumab 150 mg s.c. and Secukinumab 300 mg s.c. in Plaque Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 32 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-30.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.
Among the 54 studies testing secukinumab in Psoriasis, this one is the 8th largest by enrollment, is one of 5 that started in 2017, is one of 24 in phase 3, and was the 37th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of Athens · Sites in Greece
Ages 18–80 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Singapore General Hospital · Sites in Singapore
Ages 22–90
By country, each count listing its studies:
secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 24 · Phase 4 17
First in 2007; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 543 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 124 across the 54 interventional studies. Of the 46 that completed or were terminated, 38 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 54 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
68 studies in Psoriasis by Novartis: 3 open now, 4 under way, none of them phase 3. Of 61 finished, 41 (67%) have results posted.
Among the 68 studies in Psoriasis by Novartis, this one is the 9th largest by enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2017, is one of 30 in phase 3, and was the 47th registered.
Novartis’s Psoriasis studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing secukinumab in Psoriasis, from their registry updates:
Among Novartis’s 68 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to determine if secukinumab is effective and safe in the treatment of plaque type psoriasis
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
This study's enrollment of 543 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Browse Psoriasis studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Compared within Psoriasis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Skin Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Moderate to severe psoriasis as defined at Baseline by:
Candidate for systemic therapy. This is defined as a subject having moderate to severe chronic plaque-type psoriasis that is inadequately controlled by
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Secukinumab 150mg s.c.
Drug: Secukinumab 150 mg s.c.
Secukinumab 300mg s.c.
Drug: Secukinumab 300 mg s.c.
Placebo to secukinumab s.c
Drug: Placebo
150 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
300 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
Placebo 150 or 300 mg s.c at randomization, Weeks 1, 2, 3, 4, and 8. PASI responders at week 12 continued to receive placebo till Week 48. PASI non-responders at Week 12 received Secukinumab 300mg at Weeks 12, 13, 14, 15, 16 and every 4 weeks till Week 48
Psoriasis Area and Severity Index (PASI) 75 (Multiple Imputation)
Psoriasis Area and Severity Index (PASI) was assessed/calculated as per usual standard. result given in terms of count of participants with response in 100 imputations. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
Time frame: Week 12
Investigator's Global Assessment (IGA) Mod 2011 0/1 (Multiple Imputation)
Investigator assessed disease using a validated scale (IGA mod 2011) and rate the disease from a score of 0 (clear skin) to 4 (severe disease). result given in terms of count of participants with response in 100 imputations. The Investigator's Global Assessment (IGA) mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1.
Time frame: Week 12
Psoriasis Area and Severity Index (PASI) 90 (Multiple Imputation)
Psoriasis Area and Severity Index (PASI) was assessed/calculated as per usual standard. result given in terms of count of participants with response in 100 imputations. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
Time frame: Week 12
Efficacy of Secukinumab in Maintaining PASI 75 Response at Week 52 in Subjects Who Were PASI 75 Responders at Week 12 (Multiple Imputation)
Psoriasis Area and Severity Index (PASI) was assessed/calculated as per usual standard. result given in terms of count of participants with response in 100 imputations. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
Time frame: Week 52
Efficacy of Secukinumab in Maintaining IGA Mod 2011 0 or 1 Response at Week 52 in Subjects Who Were IGA Mod 2011 0 or 1 Responders at Week 12 (Multiple Imputation)
Investigator assessed disease using a validated scale (IGA mod 2011) and rate the disease from a score of 0 (clear skin) to 4 (severe disease). result given in terms of count of participants with response in 100 imputations. The Investigator's Global Assessment (IGA) mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1.
Time frame: Week 52
PASI 50/75/90/100 and IGA Mod 2011 0 or 1 Response Over Time (Multiple Imputation)
Number (%) of subjects with PASI 50, PASI 75, PASI 90, PASI 100 and IGA mod 2011 0 or 1 response
Time frame: week 1, week 12, week 24, week 52
American Collage of Rheumatology (ACR) Response 20/50/70
Percentage of patients who achieved ACR 20/50/70 at Week 12 and up to Week 52. The subset of patients who had active PsA at baseline included 7 patients in the secukinumab 150 mg group, 17 patients in the secukinumab 300 mg group and 4 patients in the placebo group. ACR 20, 50 or 70 responses correspond, respectively, to at least 20%, 50% or 70% improvement in comparison with baseline in the number of tender and swollen joint counts, in addition to similar improvements in at least three of five other measure of disability or disease activity
Time frame: week 12, week 24, week 52
Time to PASI 75 Response up to Week 12
Psoriasis Area and Severity Index (PASI) was assessed/calculated as per usual standard. result given in terms of count of participants with response in 100 imputations. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
Time frame: week 12
A total of 664 patients were screened and 543 patients were randomized to one of three treatment groups in the induction period: secukinumab 300 mg (n=272), secukinumab 150 mg (n=136), and placebo (n=135)
| Milestone | Secukinumab 150mg | Secukinumab 300mg | Placebo | Placebo - Secukinumab 300mg |
|---|---|---|---|---|
| Started | 136 | 272 | 135 | 0 |
| Completed | 134 | 270 | 133 | 0 |
| Not completed | 2 | 2 | 2 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 2 | 2 | 0 | 0 |
| Milestone | Secukinumab 150mg | Secukinumab 300mg | Placebo | Placebo - Secukinumab 300mg |
|---|---|---|---|---|
| Started | 134 | 270 | 4 | 129 |
| Completed | 127 | 266 | 2 | 126 |
| Not completed | 7 | 4 | 2 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 4 | 2 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 2 | 1 | 0 | 1 |
| Milestone | Secukinumab 150mg | Secukinumab 300mg | Placebo | Placebo - Secukinumab 300mg |
|---|---|---|---|---|
| Started | 136 | 272 | 6 | 129 |
| Completed | 126 | 264 | 2 | 124 |
| Not completed | 10 | 8 | 4 | 5 |
| Withdrew: Adverse event | 2 | 2 | 0 | 1 |
| Withdrew: Withdrawal by subject | 4 | 2 | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 | 1 |
| Withdrew: Pregnancy | 1 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 2 | 1 | 1 | 1 |
| Withdrew: Discontinued follow up | 0 | 2 | 0 | 0 |
Psoriasis Area and Severity Index (PASI) was assessed/calculated as per usual standard. result given in terms of count of participants with response in 100 imputations. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
| Participants | Secukinumab 150mg | Secukinumab 300mg | Placebo |
|---|---|---|---|
| Psoriasis Area and Severity Index (PASI) 75 (Multiple Imputation) | 112 | 254 | 6 |
Investigator assessed disease using a validated scale (IGA mod 2011) and rate the disease from a score of 0 (clear skin) to 4 (severe disease). result given in terms of count of participants with response in 100 imputations. The Investigator's Global Assessment (IGA) mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1.
| Participants | Secukinumab 150mg | Secukinumab 300mg | Placebo |
|---|---|---|---|
| Investigator's Global Assessment (IGA) Mod 2011 0/1 (Multiple Imputation) | 92 | 214 | 4 |
Psoriasis Area and Severity Index (PASI) was assessed/calculated as per usual standard. result given in terms of count of participants with response in 100 imputations. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
| Participants | Secukinumab 150mg | Secukinumab 300mg | Placebo |
|---|---|---|---|
| Psoriasis Area and Severity Index (PASI) 90 (Multiple Imputation) | 85 | 210 | 2 |
Psoriasis Area and Severity Index (PASI) was assessed/calculated as per usual standard. result given in terms of count of participants with response in 100 imputations. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
| Participants | Secukinumab 150mg | Secukinumab 300mg |
|---|---|---|
| Efficacy of Secukinumab in Maintaining PASI 75 Response at Week 52 in Subjects Who Were PASI 75 Responders at Week 12 (Multiple Imputation) | 94 | 235 |
Investigator assessed disease using a validated scale (IGA mod 2011) and rate the disease from a score of 0 (clear skin) to 4 (severe disease). result given in terms of count of participants with response in 100 imputations. The Investigator's Global Assessment (IGA) mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1.
| Participants | Secukinumab 150mg | Secukinumab 300mg |
|---|---|---|
| Efficacy of Secukinumab in Maintaining IGA Mod 2011 0 or 1 Response at Week 52 in Subjects Who Were IGA Mod 2011 0 or 1 Responders at Week 12 (Multiple Imputation) | 65 | 162 |
Number (%) of subjects with PASI 50, PASI 75, PASI 90, PASI 100 and IGA mod 2011 0 or 1 response
| Participants | Secukinumab 150mg | Secukinumab 300mg | Placebo | Placebo - AIN457 300 mg |
|---|---|---|---|---|
| Week 1 IGA 0/1 | 0 | 1 | 0 | 0 |
| Week 1 PASI 50 | 5 | 25 | 1 | 0 |
| Week 1 PASI 75 | 0 | 0 | 0 | 0 |
| Week 1 PASI 90 | 0 | 0 | 0 | 0 |
| Week 1 PASI 100 | 0 | 0 | 0 | 0 |
| Week 12 IGA 0/1 | 92 | 214 | 4 | 0 |
| Week 12 PASI 50 | 130 | 267 | 16 | 0 |
| Week 12 PASI 75 | 112 | 254 | 6 | 0 |
| Week 12 PASI 90 | 85 | 210 | 2 | 0 |
| Week 12 PASI 100 | 28 | 81 | 1 | 0 |
| Week 16 IGA 0/1 | 100 | 219 | 2 | 32 |
| Week 16 PASI 50 | 134 | 270 | 4 | 108 |
| Week 16 PASI 75 | 124 | 261 | 3 | 72 |
| Week 16 PASI 90 | 98 | 233 | 2 | 22 |
| Week 16 PASI 100 | 39 | 99 | 0 | 3 |
| Week 24 IGA 0/1 | 91 | 217 | 1 | 88 |
| Week 24 PASI 50 | 135 | 271 | 4 | 123 |
| Week 24 PASI 75 | 123 | 257 | 2 | 113 |
| Week 24 PASI 90 | 93 | 230 | 2 | 94 |
| Week 24 PASI 100 | 47 | 107 | 0 | 31 |
| Week 52 IGA 0/1 | 79 | 194 | 0 | 96 |
| Week 52 PASI 50 | 128 | 269 | 4 | 126 |
| Week 52 PASI 75 | 111 | 259 | 4 | 119 |
| Week 52 PASI 90 | 86 | 218 | 1 | 101 |
| Week 52 PASI 100 | 42 | 110 | 1 | 55 |
Percentage of patients who achieved ACR 20/50/70 at Week 12 and up to Week 52. The subset of patients who had active PsA at baseline included 7 patients in the secukinumab 150 mg group, 17 patients in the secukinumab 300 mg group and 4 patients in the placebo group. ACR 20, 50 or 70 responses correspond, respectively, to at least 20%, 50% or 70% improvement in comparison with baseline in the number of tender and swollen joint counts, in addition to similar improvements in at least three of five other measure of disability or disease activity
| Participants | Secukinumab 150mg | Secukinumab 300mg | Placebo | Placebo - AIN457 300 mg |
|---|---|---|---|---|
| Week 12 ACR 20 | 4 | 13 | 0 | 0 |
| Week 12 ACR 50 | 3 | 12 | 0 | 0 |
| Week 12 ACR 70 | 2 | 6 | 0 | 0 |
| Week 24 ACR 20 | 5 | 14 | 0 | 2 |
| Week 24 ACR 50 | 4 | 10 | 0 | 1 |
| Week 24 ACR 70 | 2 | 6 | 0 | 1 |
| Week 52 ACR 20 | 4 | 13 | 0 | 3 |
| Week 52 ACR 50 | 3 | 11 | 0 | 2 |
| Week 52 ACR 70 | 2 | 8 | 0 | 0 |
Psoriasis Area and Severity Index (PASI) was assessed/calculated as per usual standard. result given in terms of count of participants with response in 100 imputations. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
| days | Secukinumab 150mg | Secukinumab 300mg |
|---|---|---|
| Time to PASI 75 Response up to Week 12 | 57 (51 to 57) | 55 (29 to 57) |
Collected over 12 months. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AIN457 150 mg | 0/136 (0%) | 5/136 (3.7%) | 115/136 (84.6%) |
| AIN457 300 mg | 0/272 (0%) | 9/272 (3.3%) | 221/272 (81.3%) |
| Any AIN457 300 mg | 0/401 (0%) | 14/401 (3.5%) | 312/401 (77.8%) |
| Any AIN457 Dose | 0/537 (0%) | 19/537 (3.5%) | 427/537 (79.5%) |
| Placebo | 0/135 (0%) | 2/135 (1.5%) | 71/135 (52.6%) |
| Event | AIN457 150 mg | AIN457 300 mg | Any AIN457 300 mg | Any AIN457 Dose | Placebo |
|---|---|---|---|---|---|
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/136 | 0/272 | 0/401 | 0/537 | 1/135 |
| PsoriasisSkin and subcutaneous tissue disorders | 0/136 | 0/272 | 0/401 | 0/537 | 1/135 |
| Angina unstableCardiac disorders | 1/136 | 0/272 | 0/401 | 1/537 | 0/135 |
| Arteriosclerosis coronary arteryCardiac disorders | 1/136 | 0/272 | 1/401 | 2/537 | 0/135 |
| Crohn's diseaseGastrointestinal disorders | 1/136 | 0/272 | 0/401 | 1/537 | 0/135 |
| Tooth impactedGastrointestinal disorders | 1/136 | 0/272 | 0/401 | 1/537 | 0/135 |
| AppendicitisInfections and infestations | 0/136 | 2/272 | 2/401 | 2/537 | 0/135 |
| TonsillitisInfections and infestations | 1/136 | 0/272 | 0/401 | 1/537 | 0/135 |
| Colon adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/136 | 0/272 | 0/401 | 1/537 | 0/135 |
| Erythrodermic psoriasisSkin and subcutaneous tissue disorders | 1/136 | 0/272 | 0/401 | 1/537 | 0/135 |
| Event | AIN457 150 mg | AIN457 300 mg | Any AIN457 300 mg | Any AIN457 Dose | Placebo |
|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 41/136 | 67/272 | 97/401 | 138/537 | 13/135 |
| HyperuricaemiaMetabolism and nutrition disorders | 25/136 | 56/272 | 76/401 | 101/537 | 17/135 |
| NasopharyngitisInfections and infestations | 15/136 | 44/272 | 57/401 | 72/537 | 5/135 |
| InfluenzaInfections and infestations | 17/136 | 28/272 | 38/401 | 55/537 | 4/135 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 16/136 | 25/272 | 32/401 | 48/537 | 3/135 |
| PruritusSkin and subcutaneous tissue disorders | 12/136 | 32/272 | 36/401 | 48/537 | 11/135 |
| DiarrhoeaGastrointestinal disorders | 13/136 | 31/272 | 42/401 | 55/537 | 12/135 |
| PharyngitisInfections and infestations | 14/136 | 24/272 | 35/401 | 49/537 | 7/135 |
| CoughRespiratory, thoracic and mediastinal disorders | 13/136 | 17/272 | 25/401 | 38/537 | 2/135 |
| UrticariaSkin and subcutaneous tissue disorders | 12/136 | 24/272 | 30/401 | 42/537 | 0/135 |
| Age, Continuous(years) | Secukinumab 150mg | Secukinumab 300mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 41 ± 11.39 | 39.9 ± 12.35 | 40.1 ± 11.01 | 40.2 ± 11.78 |
| Sex: Female, Male(Participants) | Secukinumab 150mg | Secukinumab 300mg | Placebo | Total |
|---|---|---|---|---|
| Female | 37 | 67 | 27 | 131 |
| Male | 99 | 205 | 108 | 412 |
| Race/Ethnicity, Customized(Participants) | Secukinumab 150mg | Secukinumab 300mg | Placebo | Total |
|---|---|---|---|---|
| East Asian | 109 | 220 | 109 | 438 |
| Southeast Asian | 19 | 32 | 16 | 67 |
| South Asian | 1 | 0 | 0 | 1 |
| West Asian | 0 | 3 | 0 | 3 |
| other | 6 | 17 | 10 | 33 |
| not reported | 1 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Secukinumab 150mg | Secukinumab 300mg | Placebo | Total |
|---|---|---|---|---|
| Caucasian | 7 | 20 | 10 | 37 |
| Asian | 129 | 252 | 125 | 506 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Feb 2017 to primary completion in Dec 2017, 9 months.
Results were first posted in Dec 2019, 2 years after primary completion.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 9 months is below that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab